Innocrin Pharmaceuticals is a US-based, clinical-stage pharmaceutical company specializing in the development of innovative oral CYP17 lyase inhibitors.

We are focused on addressing the critical needs of patients with castration-resistant prostate cancer (CRPC), a challenging and often aggressive form of the disease. Our lead product candidate targets this specific patient population, offering a potentially ‘best-in-class’ treatment option.

Innocrin’s research and development efforts extend to exploring the potential application of these inhibitors in other hormonally-driven conditions, including breast cancer, endometriosis, and congenital adrenal hyperlplasia. We are dedicated to advancing precision medicine through targeted therapies.

Founded in 2014, Innocrin Pharmaceuticals is committed to bringing transformative medicines to patients worldwide.

CYP17 Lyase Inhibitor | Innocrin Pharmaceuticals, Inc.

Product description

Innocrin Pharmaceuticals, Inc. Durham, United States (US)

Price: N/A

Innocrin Pharmaceuticals, Inc.
Durham, United States (US)